These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 31026622)
1. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Timmers T; Ossenkoppele R; Verfaillie SCJ; van der Weijden CWJ; Slot RER; Wesselman LMP; Windhorst AD; Wolters EE; Yaqub M; Prins ND; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BNM Neurobiol Aging; 2019 Jul; 79():50-58. PubMed ID: 31026622 [TBL] [Abstract][Full Text] [Related]
2. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697 [TBL] [Abstract][Full Text] [Related]
3. Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals. Ebenau JL; Visser D; Verfaillie SCJ; Timmers T; van Leeuwenstijn MSSA; Kate MT; Windhorst AD; Barkhof F; Scheltens P; Prins ND; Boellaard R; van der Flier WM; van Berckel BNM Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):410-422. PubMed ID: 36071221 [TBL] [Abstract][Full Text] [Related]
4. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H; Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152 [TBL] [Abstract][Full Text] [Related]
5. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA; Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397 [TBL] [Abstract][Full Text] [Related]
6. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline? Funaki K; Nakajima S; Noda Y; Wake T; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M; Tabuchi H Psychogeriatrics; 2019 Jul; 19(4):325-332. PubMed ID: 30688000 [TBL] [Abstract][Full Text] [Related]
7. Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. Verfaillie SCJ; Timmers T; Slot RER; van der Weijden CWJ; Wesselman LMP; Prins ND; Sikkes SAM; Yaqub M; Dols A; Lammertsma AA; Scheltens P; Ossenkoppele R; van Berckel BNM; van der Flier WM Front Aging Neurosci; 2019; 11():7. PubMed ID: 30760996 [No Abstract] [Full Text] [Related]
8. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment. Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417 [TBL] [Abstract][Full Text] [Related]
9. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Verberk IMW; Hendriksen HMA; van Harten AC; Wesselman LMP; Verfaillie SCJ; van den Bosch KA; Slot RER; Prins ND; Scheltens P; Teunissen CE; Van der Flier WM Neurobiol Aging; 2020 May; 89():99-107. PubMed ID: 32081465 [TBL] [Abstract][Full Text] [Related]
10. The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline. Sanabria A; Alegret M; Rodriguez-Gomez O; Valero S; Sotolongo-Grau O; Monté-Rubio G; Abdelnour C; Espinosa A; Ortega G; Perez-Cordon A; Gailhajanet A; Hernandez I; Rosende-Roca M; Vargas L; Mauleon A; Sanchez D; Martin E; Rentz DM; Lomeña F; Ruiz A; Tarraga L; Boada M; Sci Rep; 2018 Feb; 8(1):3828. PubMed ID: 29491481 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal change in ATN biomarkers in cognitively normal individuals. Ebenau JL; Visser D; Kroeze LA; van Leeuwenstijn MSSA; van Harten AC; Windhorst AD; Golla SVS; Boellaard R; Scheltens P; Barkhof F; van Berckel BNM; van der Flier WM Alzheimers Res Ther; 2022 Sep; 14(1):124. PubMed ID: 36057616 [TBL] [Abstract][Full Text] [Related]
15. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517 [TBL] [Abstract][Full Text] [Related]
16. Grey zone amyloid burden affects memory function: the SCIENCe project. Ebenau JL; Verfaillie SCJ; van den Bosch KA; Timmers T; Wesselman LMP; van Leeuwenstijn M; Tuncel H; Golla SVS; Yaqub MM; Windhorst AD; Prins ND; Barkhof F; Scheltens P; van der Flier WM; van Berckel BNM Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):747-756. PubMed ID: 32888039 [TBL] [Abstract][Full Text] [Related]
17. Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging. Winer JR; Deters KD; Kennedy G; Jin M; Goldstein-Piekarski A; Poston KL; Mormino EC JAMA Neurol; 2021 Oct; 78(10):1187-1196. PubMed ID: 34459862 [TBL] [Abstract][Full Text] [Related]
18. Amyloid-β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. Pelkmans W; Legdeur N; Ten Kate M; Barkhof F; Yaqub MM; Holstege H; van Berckel BNM; Scheltens P; van der Flier WM; Visser PJ; Tijms BM Ann Clin Transl Neurol; 2021 Feb; 8(2):348-358. PubMed ID: 33421355 [TBL] [Abstract][Full Text] [Related]
19. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL; Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471 [TBL] [Abstract][Full Text] [Related]
20. Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging. Valech N; Tort-Merino A; Coll-Padrós N; Olives J; León M; Rami L; Molinuevo JL J Alzheimers Dis; 2018; 61(2):689-703. PubMed ID: 29254090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]